Cullinan Therapeutics, Inc. - Common Stock (CGEM)
CUSIP: 230031106
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 59,091,689
- Total 13F shares
- 62,610,123
- Share change
- -2,064,371
- Total reported value
- $471,432,056
- Put/Call ratio
- 8652%
- Price per share
- $7.53
- Number of holders
- 141
- Value change
- -$15,598,491
- Number of buys
- 68
- Number of sells
- 67
Quarterly Holders Quick Answers
What is CUSIP 230031106?
CUSIP 230031106 identifies CGEM - Cullinan Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 230031106:
Top shareholders of CGEM - Cullinan Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ansbert Gadicke |
3/4/5
|
Director |
—
class O/S missing
|
8,243,757
|
$102,717,212 | — | 22 Jun 2022 | |
| UBS Oncology Impact Fund L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
7,648,268
|
$95,297,419 | — | 16 Sep 2021 | |
| MPM BioImpact LLC |
13F
|
Company |
13%
|
7,648,268
|
$57,897,389 | — | 31 Mar 2025 | |
| Morana Jovan-Embiricos |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,526,260
|
$56,397,201 | — | 24 Jun 2022 | |
| Vision Scs F2 |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,476,350
|
$55,775,322 | — | 02 Aug 2022 | |
| F2 Bioscience I 2017 Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,430,964
|
$55,209,813 | — | 21 Jun 2022 | |
| BVF INC/IL |
13F
|
Company |
9.7%
|
5,750,683
|
$43,532,670 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7.1%
|
4,220,862
|
$31,951,923 | — | 31 Mar 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
6.5%
|
3,860,839
|
$29,226,551 | — | 31 Mar 2025 | |
| Lynx1 Capital Management LP |
13F
|
Company |
5.4%
|
3,215,722
|
$24,343,016 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.1%
|
3,039,731
|
$23,010,763 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4.6%
|
2,747,145
|
$20,795,888 | — | 31 Mar 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
4.1%
|
2,435,972
|
$18,440,308 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13D/G
13F
|
Company |
3.8%
|
2,191,262
|
$17,836,873 | $0 | 30 Sep 2024 | |
| Kynam Capital Management, LP |
13F
|
Company |
4%
|
2,338,629
|
$17,703,422 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
3.3%
|
1,923,855
|
$14,563,582 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
3%
|
1,752,679
|
$13,267,780 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
2.9%
|
1,723,001
|
$13,043,118 | — | 31 Mar 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
2.9%
|
1,705,960
|
$12,914,117 | — | 31 Mar 2025 | |
| VR Adviser, LLC |
13F
|
Company |
2.3%
|
1,379,965
|
$10,446,335 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
2.2%
|
1,303,221
|
$9,867,032 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
1,241,817
|
$9,402,621 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
2%
|
1,193,410
|
$9,034,114 | — | 31 Mar 2025 | |
| Nextech Invest, Ltd. |
13F
|
Company |
1.9%
|
1,141,145
|
$8,638,468 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.9%
|
1,121,138
|
$8,487,015 | — | 31 Mar 2025 | |
| BRAIDWELL LP |
13F
|
Company |
1.7%
|
980,773
|
$7,424,452 | — | 31 Mar 2025 | |
| Patient Square Capital LP |
13F
|
Company |
1.5%
|
878,897
|
$6,653,250 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.3%
|
783,177
|
$5,928,650 | — | 31 Mar 2025 | |
| Patrick Baeuerle |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
494,434
mixed-class rows
|
$5,201,228 | — | 17 Feb 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.1%
|
648,957
|
$4,912,605 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
1.1%
|
644,633
|
$4,879,872 | — | 31 Mar 2025 | |
| Foresite Capital Management VI LLC |
13F
|
Company |
1.1%
|
634,558
|
$4,803,604 | — | 31 Mar 2025 | |
| TWIN FOCUS CAPITAL PARTNERS, LLC |
13F
|
Company |
1%
|
595,489
|
$4,507,852 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.97%
|
575,531
|
$4,356,770 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.96%
|
567,999
|
$4,299,752 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.89%
|
524,385
|
$3,969,594 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.82%
|
483,889
|
$3,663,039 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.82%
|
481,832
|
$3,647,469 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.72%
|
424,262
|
$3,211,663 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.61%
|
363,008
|
$2,747,971 | — | 31 Mar 2025 | |
| Thomas Ebeling |
3/4/5
|
Director |
—
class O/S missing
|
186,653
|
$2,426,489 | — | 10 Jun 2024 | |
| Jeffrey Trigilio |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
233,919
mixed-class rows
|
$2,166,809 | — | 22 Feb 2024 | |
| UBS Group AG |
13F
|
Company |
0.47%
|
278,819
|
$2,110,660 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.45%
|
263,817
|
$1,997,095 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.41%
|
241,343
|
$1,826,966 | — | 31 Mar 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.37%
|
221,430
|
$1,676,000 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.32%
|
188,030
|
$1,423,388 | — | 31 Mar 2025 | |
| Voss Capital, LP |
13F
|
Company |
0.3%
|
175,000
|
$1,324,750 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.27%
|
161,057
|
$1,219,201 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.23%
|
136,414
|
$1,032,655 | — | 31 Mar 2025 |
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock (CGEM) as of Q2 2025
As of 30 Jun 2025,
Cullinan Therapeutics, Inc. - Common Stock (CGEM) was held by
141 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
62,610,123 shares.
The largest 10 holders included
MPM BIOIMPACT LLC, BVF INC/IL, Lynx1 Capital Management LP, BlackRock, Inc., DEERFIELD MANAGEMENT COMPANY, L.P., VANGUARD GROUP INC, CITADEL ADVISORS LLC, Blue Owl Capital Holdings LP, FRANKLIN RESOURCES INC, and Kynam Capital Management, LP.
This page lists
141
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
145
Q2 2025 holders
141
Holder diff
-4
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.